Critical review of encapsulation methods for stabilization and delivery of astaxanthin

Nauman Khalida,b and Colin J. Barrya*

aCentre for Chemistry and Biotechnology, Deakin University, Waurn Ponds, Victoria 3217, Australia
bSchool of Food and Agricultural Sciences, University of Management and Technology, Lahore 54000, Pakistan

*Corresponding author: Colin J. Barrow, Centre for Chemistry and Biotechnology, Deakin University, Geelong, Victoria 3217, Australia.
Tel: +61 352271318; Fax: +61 352271040; E-mail: cbarrow@deakin.edu.au

DOI: 10.31665/JFB.2018.1129

Received: October 24, 2017; Revised received & accepted: January 23, 2018


Abstract

Astaxanthin is an important carotenoid pigment and potent antioxidant with proven health benefits. It is primarily obtained from algae or bacteria and is the natural colorant in crustaceans and salmonids. However, this pigment readily degrades in the presence of light and oxygen and has low absorption rates in the human digestive system. Different encapsulation strategies have been adopted to improve astaxanthin physical stability and bioavailability for nutritional use. This review summarizes and compares different encapsulation techniques and matrices applied to astaxanthin. Typical methods for encapsulation include high pressure homogenization, nanodispersions, liposomes and nanoparticles. More recently low energy methods like membrane and microchannel emulsification have been used to improve astaxanthin stability and delivery. Despite the use of numerous delivery methods, improved delivery systems for concentrated astaxanthin formulations are still required. In addition, not all methods have undergone comprehensive in vivo studies that are required to assure the bioavailability of encapsulated astaxanthin.

Keywords: Astaxanthin; encapsulation; high energy methods; nanodispersions; bioavailability; food matrices.

1. Introduction

Astaxanthin is a natural carotenoid pigment, synthesized by some marine microorganisms and concentrated in higher order marine animals (Lorenz and Cysewski 2000). The main commercial sources of astaxanthin are microalgae and crustaceans (Ambati et al. 2014). The microalgae Haematococcus pluvialis, Botryococcus braunii, Chlorella zofingiensis and Chlorococcum spp. are the richest sources of astaxanthin (Johnson and An 1991). Haematococcus pluvialis has the highest concentration of ketocarotenoid astaxanthin, at up to 2.0–3.0% (w/w) on a dry weight basis (Lemoine and Schoeils 2010). Haematococcus pluvialis, under stress conditions of light intensity and phosphate deprivation, accumulates astaxanthin and its fatty acid ester derivatives (Boussiba and Vonshak 1991). Astaxanthin can reduce skin DNA damages and is a powerful antioxidant. The antioxidative activity of astaxanthin on cells is greater than that of vitamin C and E, lutein, β-carotene, lycopene or catechins (Naguib 2000). Moreover, the antioxidative activity of astaxanthin is 100- to 500-fold greater than α-tocopherol (Naguib 2000). Around the mid-1990’s a range of companies began to market astaxanthin as a natural dietary supplement. These companies include Soft Gel Technologies, Inc., Mera Pharmaceuticals, La Haye Laboratories and Cyanotech in the USA, Britannia Healthin the UK and Itano in Japan.

Astaxanthin contains two terminal rings joined by a conjugated polyene system and the two asymmetric carbons located at the 3, 3′ positions of the benzene ring contain hydroxyl groups (–OH) and at 4, 4′ positions haveketone (–O) groups, on the either end of the molecule. Astaxanthin exists in three configurational isomers, two enantiomers (3S, 3′S and 3R, 3′R) and in meso form (3R, 3′S) (Fig. 1) (Higuera-Ciapara et al. 2006). Among these isomers, the 3S, 3′S is the most abundant in nature and Haematococcus sp.
Khalid et al. Critical review of encapsulation methods

Figure 1. Configuration of different astaxanthin isomers in the trans form.

Figure 2. Free astaxanthin, mono and diester forms of astaxanthin (Miao et al. 2006).

Astaxanthin has been used in a range of applications as an antioxidant, in fish (salmon and trout) feeds, and in human health as a nutraceutical. Commercial astaxanthin acts as an anti-inflammatory agent and the effectiveness is similar to that of inflammatory drugs like aspirin or ibuprofen. In vitro experiments, in vivo pre-clinical studies and early-stage clinical trials indicate that astaxanthin itself, or in conjunction with other components, may prevent or even cure some disorders.

Astaxanthin is utilized in nutraceutical, food, feed and pharmaceuticals. The majority of astaxanthin used in feed is synthetic, however naturally produced astaxanthin is preferred in food due to its isomeric purity. Astaxanthin in the market is available in different delivery vehicles including energy drinks, capsules, creams, biomasses, tablets, soft gels and extracts. In some commercial applications astaxanthin is combined with other functional compounds like other carotenoids, multivitamins, omega-3 fatty acids or herbal extracts. Numerous patents exist that depict functional attributes of these nutraceutical products. There is not Recommended Daily Intake (RDI) for astaxanthin, but nutritional products provided doses up to 300 mg per day based on clinical studies. Functional foods normally contain significantly lower amounts since they normally do not aim to provide a daily amount in a single serving. Dietary supplements containing lipid extracts of Haematococcus pluvialis containing varying levels of astaxanthin are marketed worldwide, and were approved by the United States Food and Drug Administration (USFDA) as a New Dietary Ingredient in 1999. They are now marketed for use in dietary supplements in many countries.

Astaxanthin is very effective in the treatment of ocular inflammation (Suzuki et al. 2006) and also prevents skin inflammation and thickness against UV radiation (Hama et al. 2012; Santos et al. 2012). Moreover, a supercritical carbon dioxide extract of Haematococcus algaewas shown to be effective against sunburn over a period of two weeks. Also, feed antioxidant potential increased significantly after addition of astaxanthin in the diet of rabbits (Augusti et al. 2012), with a similar effect observed after astaxanthin incorporation in the diet after ethanol induced gastric ulcer in rats (Kamath et al. 2008). Astaxanthin and its esters also have anti-lipid peroxidation activity and inhibited 80% lipid peroxidation in rats with induced skin cancer (Kamath et al. 2008) and gastric ulcers. Astaxanthin addition in the diet improved diabetes symptoms by protecting pancreatic β-cells against glucose toxicity and also prevented diabetic nephropathy(Kim et al. 2009; Manabe et al. 2008). Moreover astaxanthin in combination with α-tocopherol inhibited oxidative stress in streptozotocin-diabetic rats (Nakano et al. 2008).
Critical review of encapsulation methods

Khalid et al.

Figure 3. Systematic presentation of astaxanthin encapsulation using a two-step homogenization procedure.

Astaxanthin improved heart functionality, with the addition of 0.08% astaxanthin in mice diet increasing the functionality of heart mitochondrial membrane and contractility index in comparison to a control (Gross and Lockwood 2005). Similarly, astaxanthin had a strong effect on blood pressure reduction in normotensive Wistar Kyoto rats, spontaneously hypertensive rats and stroke prone spontaneously hypertensive rats (Monroy-Ruiz et al. 2011). Astaxanthin at the dosages of 100 mg and 500 mg/100g also restricted the activity of oxidative stress enzymes that in turn improves heart functionality (Augusti et al. 2012).

Astaxanthin and its derivatives have excellent antitumor activity in comparison to other carotenoids like β-carotene and canthaxanthin (Chew and Park 2004; Chew et al. 1998). Astaxanthin inhibited the growth of embryonic fibroblasts, prostate cancer cells, breast cancer cell and also restricted the growth of fibrosarcoma (Palozza et al. 2009). Carcinogenesis and mouse skin papillomas were significantly inhibited by astaxanthin treatment (Maoka et al. 2012). Moreover, astaxanthin extracts inhibited the growth of human colon cancer cells by stopping cell cycle progression and promoting apoptosis (Palozza et al. 2009).

3. Encapsulation processes for astaxanthin

Encapsulation technology can be very effective for enhancing the solubility, stability and bioavailability of astaxanthin. Astaxanthin stability and bioavailability is significantly improved by different encapsulated products and formulations (Anarjan et al. 2011a; Anarjan et al. 2014b; McClements et al. 2014; McClements and Rao 2011; Pu et al. 2011; Ribeiro et al. 2005; Tachaprunin et al. 2009). Physicochemical properties such as stability is also improved by encapsulation. This review summarizes and compares different encapsulation strategies and formulations for enhancing stability and bioavailability of astaxanthin.

Cost-effective astaxanthin encapsulation formulations include different emulsions, colloidal suspensions, and nanoparticles. These formulations are applied in food, pharmaceutical and nutraceutical products. However, the development and optimization of these formulations is not straightforward, as emulsifier concentration, heating temperature and pH impact the production, storage stability and bioavailability of astaxanthin formulations. Moreover, slight changes in droplet/particle size can give different color shades and impacts the final look and feel of the product (Higuera-Ciapara et al. 2004; McClements 2012; Ribeiro et al. 2010).

3.1. Oil in water (O/W) emulsions

Oil-in-water (O/W) emulsions contain mixtures of dispersed and continuous phase in a well-defined volume fraction. In O/W emulsions, astaxanthin is dissolved in the oil phase and constitutes the dispersed phase, where this dispersed phase can be produced by various emulsification processes. Delivery as emulsions may increase the absorption of astaxanthin both in vitro and in vivo, depending upon the droplet size. Moreover, the solubility and disperse-ability of astaxanthin is significantly improved in emulsified form. Sub-micron emulsified droplets are stable against coalescence and sedimentation over long term storage. Different homogenization techniques are used to encapsulate astaxanthin, these include high pressure homogenization, membrane emulsification, microchannel emulsification and phase inversion temperature (PIT). The effectiveness of these processes is described below.

3.1.1. High pressure homogenization

Astaxanthin like other carotenoids needs a specific temperature range for solubility, and to avoid crystallization and degradation (Ribeiro et al. 2005). Moreover, the kinetics of droplet breakup and stabilization by high pressure homogenization requires an optimum interfacial balance to avoid coalescence (Khalid et al. 2017b; McClements and Rao 2011). A two-step homogenization procedure is adopted to produce fine droplets of astaxanthin loaded emulsions (Fig. 3). The first step involves production of a premix emulsion either by rotor-stator homogenization or simply by stirring. This premix is later passed through high pressure homogenization in order to get fine emulsion droplets (Khalid et al. 2017b; Ribeiro et al. 2010; Affandi et al. 2011).

The astaxanthin loaded dispersed phase is produced by dissolving astaxanthin in different vegetable oils or medium chain triacylglycerols (MCT) with heating to over 100 °C (Fig. 4a). Temperature reduction and fluctuation is an important step in avoiding degradation of astaxanthin, as high temperature results in interconversion of isomeric forms of astaxanthin (Fig. 4b). The reduction in temperature should be as fast as possible to increase the efficiency of encapsulation. A range of studies have been conducted to encapsulate astaxanthin using high pressure homogenization. Recently, Khalid et al. encapsulated different astaxanthin extracts in nanoemulsions via two step high pressure homogenization using modified lecithin and sodium caseinate as emulsifiers. The formulated nanoemulsions at 100 MPa have droplet sizes < 170 nm and have encapsulation efficiency > 70% after 30 days of storage (Khalid et al. 2017b). Sotomayor-Gerding et al. (2016) encapsulated 0.5% purified astaxanthin in linseed loaded O/W nanoemulsions with varying speed of homogenization from 5 to 100 MPa and significant reduction of droplet size was observed at 100 MPa with an average droplet diameter of 134 nm. The astaxanthin nanoemulsions were stable against a range of environmental stress. In another study, supercritical extracted astaxanthin was encapsu-
Astaxanthin is also encapsulated in different nanodispersions, either using low energy methods or high energy methods. Aflandi and co-workers did a comprehensive study of encapsulation of astaxanthin using nanodispersions as the main carrier (Anarjan et al. 2014a; Anarjan et al. 2015; Anarjan et al. 2014b; Anarjan et al. 2013; Anarjan and Ping Tan 2013; Anarjan and Tan 2013b; Anarjan and Tan 2013c; Anarjan and Tan 2013d; Anarjan et al. 2011b; Anarjan et al. 2012).

In most of these studies, highly purified astaxanthin (> 90%) was used to prepare the nanodispersions using a solvent displacement method. In this solvent displacement method (Fig. 5) astaxanthin was dissolved in a mixture of dichloromethane and acetone, with the aqueous phase containing the emulsifiers and stabilizer mixtures. The organic and aqueous phases are mixed with different high shear homogenizers, followed by solvent removal using rotor evaporation. The astaxanthin nanodispersions with particle sizes of < 100 nm were stable against different pHs except near the isoelectric point, salt (NaCl, CaCl2) and at different temperatures (Anarjan et al. 2014a). Similarly, response surface methodology was used to investigate the effect of different homogenization times (0.5–20 min) and speeds (1,000–9,000 rpm) on nanodispersions via the solvent displacement method. The optimized conditions for astaxanthin encapsulation include homogenization at 6,000 rpm for 7 min (Anarjan et al. 2015).

Astaxanthin is also stabilized in nanodispersions using natural emulsifiers like sodium caseinate, using similar methodology to the solvent displacement method described previously. Multiple-response optimization predicted stable nanodispersions at 30 MPa with three passes (Anarjan et al. 2011a). The effect of different polysaccharides on stabilization of astaxanthin nanodispersions was investigated by Anarjan and Ping Tan (2013). They used 0.3% (w/w) methyl cellulose, pectin, xanthan gum and gum Arabic as the main polysaccharides to stabilize 0.3% (w/w) astaxanthin using a solvent evaporation technique. The molecular structure of polysaccharides directly affects the stability of astaxanthin. Gum Arabic addition not only improved the physical stability but also gave the smallest particle size (Anarjan and Ping Tan 2013). Moreover, the effect of different polysaccharides and gelatin was also investigated together with sucrose olate and sodium caseinate as emulsifier to stabilize astaxanthin loaded nanodispersions. The addition of sodium caseinate in a gelatinized mixture improved the chemical stability of astaxanthin, while the addition of sucrose olate gave the smallest nanodispersion particle size (121 nm) (Anarjan et al. 2014b). The same research group also uses natural antioxidants to improve the stability of astaxanthin in nanodispersions. The addition of 0.4% α-tocopherol in combination with ascorbic acid improved the chemical stability of astaxanthin, while the addition of sucrose olate improved the stability of astaxanthin in nanodispersions (Anarjan et al. 2013).

Similarly, solid lipid nanoparticles can be produced using high pressure homogenization by melting the lipid at low temperature below its melting point. Li et al. (2016) encapsulated astaxanthin in solid lipid nanoparticles using stearic acid, glycerin monostearate, and glycerol distearates in soybean oil as the dispersed phase, while deionized water containing Tween 20 was used as the continuous phase. The different phases were mixed together using high pressure homogenization. 1% stearic acid was added as a lipid carrier that improved the particle size, and thermal stability of astaxanthin in nanoparticles.

3.1.3. Membrane and microchannel emulsification

Low energy methods are favorable for encapsulation of sensitive bioactive compounds. These methods improve the long-term storage stability of encapsulated compounds, however, scale-ability of the production process is still the limiting factor in low energy emulsification techniques. Among low energy methods, membrane and microchannel emulsification (MCE) are the prominent techniques.

Membrane emulsification is a process that forms emulsion by injecting a dispersed phase or premix through a microporous membrane into the continuous phase. In the former case, fine droplets are produced directly at the membrane/continuous phase interface, whereas in the latter case, pre-existing droplets are homogenized by passing premix through the membrane (Vladisavljevic et al. 2012). A microporous glass membrane called Shirasu porous glass (SPG) membrane was originally used as the emulsification device (Nakashima et al. 2000). The droplet size is largely depended upon membrane pore size (Nakashima et al. 2000). Typical monodispersed droplets are produced with coefficient of variation (CV) of
The term MCE was coined by Kawakatsu et al. (1997) and has the capability to form monodisperse emulsion droplets by using microchannel (MC) arrays precisely fabricated on single-crystal silicon microchips (Kawakatsu et al. 1997) or stainless steel microchips (Kobayashi et al. 2012). These MC arrays can be fabricated as microgrooves horizontally to the microchip surface (Kawakatsu et al. 1997) or vertically as straight-through microholes (Kobayashi et al. 2002). The grooved microchips exhibit low droplet productivity due to limited numbers of MCs, but is extremely productive in elucidating droplet generation behavior in MCs. The straight-through microchips consist of several hundreds of thousands of MCs and have monodisperse droplet productivity even at a dripping regime of 50 mL h⁻¹ (Kobayashi et al. 2002).

Sugiura et al. (2001) proposed an interfacial tension-driven droplet formation mechanism to form channels with an elongated section. The model for predicting droplet diameter in MCE was also presented and is based on droplet formation mechanisms and experimental observation (Sugiura et al. 2001b, Sugiura et al. 2002b). Monodisperse emulsion droplets with diameters of 1 μm to 500 μm and coefficient of variation below 5% have been successfully formulated through MCE (Vladisavljevic et al. 2012). The MCE has been used to produce a range of encapsulated dispersions with improved properties, such as β-carotene (Nieves et al. 2008), oleuropein (Souilem et al. 2014), γ-oryzanol (Khalid et al. 2017a), L-ascorbic acid (Khalid et al. 2015a, Khalid et al. 2015b, Khalid et al. 2015c), quercetin (Khalid et al. 2015a, Khalid et al. 2015b, Khalid et al. 2015c) and astaxanthin (Khalid et al. 2017c).

Monodisperse O/W emulsions encapsulating different commercial extracts of astaxanthin (10–20% astaxanthin) has been recently produced by MCE (Khalid et al. 2017c). The experimental setup consists of a module containing an asymmetric straight through MCE array plate with 13,752 discrete 10 × 104 μm microslots, connected to a circular microhole with a diameter of 10μm, various peristaltic pumps for delivering dispersed and continuous phases and a microscopic video system for recording the droplet generation process. The dispersed phase constitutes different astaxanthin extracts in MCT oil without any ingredient addition and the dispersed phase is prepared at room temperature without any heating. The continuous phase contains 1% (w/w) of a range of emulsifiers like modified lecithin, sodium caseinate, decaglycerol monolaurate, decaglycerol monolaurate and SDS. The MCE was conducted at a relative low dispersed phase flow rate of 1 mLh⁻¹. Successful MCE was conducted with a d₅₀ of 35–37 μm and relative span factor < 0.25. The astaxanthin encapsulation was highly dependent on the type of emulsifiers and the extract type used during MCE (Fig. 6). Better droplet productivity was achieved with 20% AstaReal astaxanthin with 1% (w/w) decaglycerol monolaurate as the optimized emulsifier. The astaxanthin loaded O/W emulsion droplets

less than 10% (Vladisavljevic et al. 2012). Membrane emulsification requires relatively small shear stress and low energy input (10⁴–10⁶ J m⁻³) to prepare emulsions than conventional emulsification devices (10⁴–10⁶ J m⁻³) (Schröder et al. 1998). A variety of materials are used to conduct membrane emulsification for the production of O/W or W/O emulsions. These includes uniform porous glass (Nakashima et al. 2000), polypropylene hollow fibres (Vladisavljevic et al. 2012), ceramics (Schröder and Schubert 1999), polytetrafluoroethylene (Yamazaki et al. 2003) and silicon nitride (Zhu and Barrow 2005). The surface of the membrane must be completely wetted with continuous phase for production of monodisperse emulsions. Based upon geometry, there are a variety of membrane emulsification, such as dead end type (Arnot et al. 2000), cross flow type (Vladisavljevic and Williams 2005), vibrating type (Zhu and Barrow 2005) and rotating type membrane emulsification (Josceleyne and Trägårdh 2000). Membrane emulsification can be used to produce particles from a wide variety of organic and inorganic materials, including hydrogels, polymers, inorganic oxides, metals and solid lipids (Vladisavljevic et al. 2012).

Ribeiro et al. (2005) encapsulated astaxanthin in O/W emulsions using repeated premix membrane emulsification. They used 80% pure crystalline astaxanthin in myggiol as the dispersed phase, while the aqueous phase contained two different emulsifiers (Tween 20 and whey protein isolate in equal concentrations). The pressure in the membrane was varied between 5 to 15 bars and the dispersed phase fraction varied between 10% to 40%. The premix O/W emulsions were passed three times through apolyamide 6,6 membrane with pore size of 0.8 μm. Increased pressure and number of repetition resulted in narrow size droplet distribution. The total astaxanthin concentration in O/W emulsions decreased to about 30% after three weeks of storage, while no coalescence was observed during the evaluated storage period (Ribeiro et al. 2005).

The model for predicting droplet diameter in MCE was also presented and is based on droplet formation mechanisms and experimental observation (Sugiura et al. 2001b, Sugiura et al. 2002b). Monodisperse emulsion droplets with diameters of 1 μm to 500 μm and coefficient of variation below 5% have been successfully formulated through MCE (Vladisavljevic et al. 2012). The MCE has been used to produce a range of encapsulated dispersions with improved properties, such as β-carotene (Nieves et al. 2008), oleuropein (Souilem et al. 2014), γ-oryzanol (Khalid et al. 2017a), L-ascorbic acid (Khalid et al. 2015a, Khalid et al. 2015b, Khalid et al. 2015c), quercetin (Khalid et al. 2015a, Khalid et al. 2015b, Khalid et al. 2015c) and astaxanthin (Khalid et al. 2017c).

Monodisperse O/W emulsions encapsulating different commercial extracts of astaxanthin (10–20% astaxanthin) has been recently produced by MCE (Khalid et al. 2017c). The experimental setup consists of a module containing an asymmetric straight through MCE array plate with 13,752 discrete 10 × 104 μm microslots, connected to a circular microhole with a diameter of 10μm, various peristaltic pumps for delivering dispersed and continuous phases and a microscopic video system for recording the droplet generation process. The dispersed phase constitutes different astaxanthin extracts in MCT oil without any ingredient addition and the dispersed phase is prepared at room temperature without any heating. The continuous phase contains 1% (w/w) of a range of emulsifiers like modified lecithin, sodium caseinate, decaglycerol monolaurate, decaglycerol monolaurate and SDS. The MCE was conducted at a relative low dispersed phase flow rate of 1 mLh⁻¹. Successful MCE was conducted with a d₅₀ of 35–37 μm and relative span factor < 0.25. The astaxanthin encapsulation was highly dependent on the type of emulsifiers and the extract type used during MCE (Fig. 6). Better droplet productivity was achieved with 20% AstaReal astaxanthin with 1% (w/w) decaglycerol monolaurate as the optimized emulsifier. The astaxanthin loaded O/W emulsion droplets

![Image](96x168 to 510x732)

Figure 5. Schematic representation of the astaxanthin loaded nanodispersions formed through the solvent displacement method.
remained stable at 25 °C with encapsulation efficiency of > 98% during 15 days of storage at room temperature (Khalid et al. 2017c).

3.1.4. Encapsulation by phase inversion and high internal phase emulsions methods

O/W emulsions may undergo phase inversion to W/O emulsions during heating and in the presence of ethoxylated non-ionic emulsifiers. At phase inversion temperatures, the hydrophilic and lipophilic properties of emulsifier are well balanced and nullify the interfacial activity of oil and water phases. Emulsification at phase inversion temperatures is called the phase inversion emulsification method or PIT method. The PIT method has the ability to produce emulsions with droplet diameter of 100 nm with an arrow size. The stability of the resultant emulsions was dependent upon storage temperature and rapid cooling is required soon after producing the emulsions (Rao and McClements 2010).

However, there are not many studies reporting encapsulation of astaxanthin using the PIT method for food grade applications. Ribeiro and Schubert (2004) reported nanosized carotenoid loaded O/W emulsions for non-food grade applications. They used cetostearyl poly(oxyethylene (12) glycol) and glyceryl monostearate as the emulsifying agents to formulate O/W emulsions using the PIT method. The composition included dissolution of astaxanthin and lycopene in dycapryl ether, which served as the oil phase. The emulsions were initially formulated at 74 °C with rapidly cooling at 25 °C. The $d_{32}$ of the emulsions were 80 nm, while the dispersity of the emulsions was between 40 and 200 nm. The total astaxanthin and lycopene concentration was around 0.3 and 3.5 g L$^{-1}$ with no significant degradation of astaxanthin and lycopene (Ribeiro and Schubert 2004).

Particle stabilized emulsions are becoming more widely utilized as nutraceutical carriers in both food and dietary supplements (Tan et al. 2017). These emulsions have outstanding stability, palatability and bioavailability (Dickinson 2010). High internal phase emulsions (HIPEs) with volume fractions exceeding 0.74 have numerous applications in the fields of gene delivery and cancer therapy. Astaxanthin can be encapsulated in HIPEs by high internal phase emulsions. The thick interfacial layer around the droplets prevent oxidation, while the low water fraction in HIPEs extend the shelf life of emulsions and also improved gastrointestinal stability (Tan et al. 2017).

Ribeiro and Cruz (2005) formulated highly concentrated emulsions encapsulating lycopene and astaxanthin using high pressure homogenization. They concentrated the volume fraction of the dispersed phase up to 94% by removing the aqueous phase using centrifugation up to 38,000 g. Moreover, the concentrated emulsions were called as “biliquid foam”. The droplet size of the biliquid foams were changed by changing the emulsifier-to-oil ratio. The droplet size varied between 100 to 800 nm by varying the dispersed phase concentration from 10 to 50% (Fig. 7). After concentration and centrifugation, the biliquid foam shows a transparent and elastic structure. Moreover, no coalescence of the droplets was observed and O/W concentrated emulsions have a good viscoelastic profile (Ribeiro and Cruz 2005).

3.1.5. Liposomes and nanoparticles

Liposomes are microscopic phospholipid bubbles with a bilayered membrane structure. Liposomes are mostly used to deliver lipophilic drugs, but liposomes have numerous applications in the fields of gene delivery and cancer therapy. Astaxanthin can be encapsulated in liposomes as a targeted drug vehicle. The double layer of liposomes is normally made from lecithins of different purities. Upon hydration and input of mechanical energy lecithin molecules orient themselves in double layers, with the lipophilic part toward the center and the hydrophilic part toward the outer surface. Liposomes greatly increase the bioavailability of astaxanthin and other lipophilic bioactives. The size of the liposomes can be adjusted using mechanical forces and a range of production methods, and have typical diameters of less than 100 nm with clear physical appearance.

The solubility of astaxanthin in phospholipids is very low, and dissolution cannot be performed at higher temperatures, since phospholipids decomposed at 180 °C. To avoid decomposition, astaxanthin and phospholipids are dispersed in an organic phase.
and then the solvent is removed under reduced pressure. Recently, Kamezaki et al. (2016) encapsulated astaxanthin in liposomes together with different vitamin E derivatives. In this system the antioxidant activity increased significant when astaxanthin was co-administrated with vitamin E.

Astaxanthin loaded nanoparticles have droplet sizes between 100 to 300 nm (Aizuddin et al. 2014; Bharathiraja et al. 2016). Mostly, nanoparticles are formulated using a solvent displacement method or emulsion evaporation method. Higuera-Ciapara et al. (2004) encapsulated astaxanthin in a chitosan matrix using a solvent evaporation technique. They used glutaraldehyde as the cross-linking agent and the microcapsules were chemically stable over a period of eight weeks. Similarly, Tachaprutinun et al. (2009) encapsulated astaxanthin in polymeric nanospheres by a solvent displacement method. They compared the three polymers poly(vinylalcohol-co-vinyl-4-methoxycinnamate), poly(ethylene oxide)-4-methoxycinnamoylphthaloylchitosan and ethylcellulose, and among these poly(ethylene oxide)-4-methoxycinnamoylphthaloylchitosan nanoparticles shows 98% encapsulation efficiency of astaxanthin with loading efficiency of 40% (w/w).

In another study, Tamjidi et al. (2014) formulated food grade astaxanthin-loaded nanostructured lipid carriers using Tween 20 and lecithin as the emulsifiers. The lipid nanocarriers were oleic acid and glyceryl behenate, while a melt emulsification–sonication technique was used to formulate the nanocarriers. Oleic acid was a better carrier than glyceryl behenate and exhibited good particle size and dispersity index. Kittikaiwan et al. (2007) encapsulated astaxanthin using 80 mol% deacetylated chitosan and the astaxanthin was coated with chitosan five times in the form of multilayers to form a thin chitosan film. The chitosan capsules had uniform shape with diameters from 0.35 to 0.5 cm with 100 μm film thickness. The chitosan film protected the astaxanthin from degradation.

Astaxanthin has also been encapsulated using particle formation techniques based on supercritical fluids, such as rapid expansion of supercritical solutions (RESS). The Supercritical Fluid Extraction of Emulsions (SFEE) technique combines the efficiency of supercritical fluid as the antisolvent for the formation of particles in combination with emulsification processes to formulate the nanoparticles (Cocero et al. 2009). Astaxanthin from shrimp-residue was encapsulated by Mezzomo et al. (2012) via the SFEE technique using the modified starch Hi-Cap 100 as the wall material and dichloromethane as the primary solvent.

Astaxanthin was also encapsulated in β-cyclodextrin inclusion complex (Chen et al. 2007) and the heat stability of the inclusion complex was greatly enhanced, moreover the aqueous solubility of the inclusion complex was slightly increased. Similar results were also reported by Kim et al. (2010), when they used an inclusion complex of astaxanthin with β-cyclodextrin in a ratio of 1:200. The storage stability, antioxidant activity and radical scavenging activity of astaxanthin loaded in hydroxypropyl-β-cyclodextrin inclusion complex was improved in comparison to free astaxanthin (Yuan et al. 2013).

### 3.1.6 Astaxanthin encapsulation by drying methods

Microencapsulation of astaxanthin in different powders was obtained either by spray drying or freeze drying. Different coating/wall materials were used to microencapsulate astaxanthin, including soluble corn fiber, whey protein isolates, sodium caseinate, maltodextrin, gum arabica and chitosan (Higuera-Ciapara et al. 2004; Bustos-Garza et al. 2013; Shen and Quek 2014). Shen and Quek (2014) used spray drying to encapsulate astaxanthin in wall material composed of blends of milk proteins and soluble corn fiber. Firstly, fine emulsions were produced using a two-step homogenization process and later the fine emulsions were spray dried using an atomizing spray nozzle with a rotational speed of 25,000 n min⁻¹. The reconstituted emulsions showed good physical stability with an encapsulation efficiency of about 95%. The astaxanthin oleoresin from Haematococcus pluvialis was dispersed in aqueous solutions with soy lecitin as emulsifier and later spray dried using gum arabica and whey protein isolates in combination with inulin or maltodextrin. Whey protein alone or combined with gum arabica exhibited the best encapsulation efficiency of 61.2–70.1% (Bustos-Garza et al. 2013). Most of the microencapsulated spray dried astaxanthin powders showed first order degradation kinetics, which depended upon the extraction procedure and core wall to oil ratios (Bustos-Garza et al. 2013; Pu et al. 2011).

Freeze drying methodology was applied mostly in solvent displacement or solvent evaporation formulations with a maximum payload of over 85% (Tachaprutinun et al. 2009). Gomez-Estaca et al. (2016) encapsulated shrimp waste extracted astaxanthin using complex coacervation with gelatin-cashew gum as core wall material followed by freeze drying to get the astaxanthin powder, although the encapsulation efficiency from was rather low at only

---

**Figure 7. Schematic presentation of astaxanthin loaded biliquid foams.** Reproduced with modification from Ribeiro and Cruz (2005).
60%. Moreover, the microencapsulated powder retarded the degradation of astaxanthin during the evaluated storage time (Gomez-Estaca et al. 2016).

4. Bioavailability of astaxanthin encapsulated formulations

Bioavailability of non-encapsulated astaxanthin has mostly been conducted as Haematococcus meal, with results indicating that a daily intake of 5 mg astaxanthin in a capsular form is rapidly metabolized over a period of 24 h. The intestinal absorption of carotenoids depends upon different factors like carotenoid type, dosage type and level, matrix of delivery, molecular linkage, genetic factors and various interactions among these factors (Parada and Aguilar 2007). The various steps of digestion, absorption and plasma transport of dietary carotenoids in mammals have been reviewed (Furr, and Clark, 1997). In plasma, different-nutritional carotenoids such as β-carotene and lycopene are mostly transported by very low-density lipoproteins (VLDLs) and low-density lipoproteins (LDLs), while polar carotenoids, such as zeaxanthin or lutein, are more likely to be transported by LDLs and high-density lipoproteins (HDLs). Astaxanthin is primarily transported in plasma via lipoproteins (Osterlie et al., 2000).

In vitro cell models are effective for investigating the cellular uptake of encapsulated astaxanthin by intestinal simulated fluids (Anarjan and Tan 2013a; Anarjan et al. 2011b; Anarjan et al. 2012; Khalid et al. 2017b). Accessibility of encapsulated astaxanthin is highly dependent on emulsifiers. Recently, Khalid et al. (2017b) evaluated the bioaccessibility of astaxanthin nanoemulsions in simulated gastrointestinal fluids using modified lecithin and sodium caseinate as emulsifiers. The bioaccessibility (Fig. 8a) of encapsulated astaxanthin was significantly higher in modified lecithin (33%) in comparison to sodium caseinate (6%). Colloidal astaxanthin composed of different mixtures of polysorbate 20, gum arabica and sodium caseinate improved the cellular uptake of astaxanthin in human colonic carcinoma HT-29 cell lines (Anarjan et al. 2012). The results agree with previous findings of Ribeiro et al. (2004) and Ribeiro et al. (2006), where mixtures of whey proteins in combination with TWEEN 20 or sucrose laurate significantly increased astaxanthin or lycopene cellular uptake from emulsified forms. In a similar cell line model (HT-29), astaxanthin cellular uptake increased by 2981 fmol/cell, when astaxanthin was delivered in nanodispersed form, formulated through a precipitation and condensation process (Anarjan et al. 2011b). Anarjan and Tan (2013a) evaluated the cellular uptake of encapsulated astaxanthin in selected food systems (skimmed milk, deionized water and orange juice) using T-29 cell lines. The cellular uptake was higher in skimmed milk (Fig. 8b) when compared with orange juice and deionized water. Moreover, the bioavailability was also lowest in deionized water. Milk proteins and dietary fats have positive effects on cellular uptake and on bioavailability of carotenoids (Castenmiller and West 1998). Microencapsulating astaxanthin in calcium alginate matrix through emulsion gelation technology improved the solubility of astaxanthin and these microcapsules also exhibited good cytostatic activity on adipose-derived stem cells (Zhang et al. 2017).

Liposomal encapsulation also improved the cellular uptake of astaxanthin, lycopene and β-carotene when formulated with phosphatidylycholine. The cellular uptake was more effective than that for emulsified astaxanthin with Tween 20 (Fig. 8c). However, the effectiveness was similar to when a combined mixture of Tween 20 and Whey protein was used as emulsifiers in O/W emulsions (Ribeiro et al. 2010).

5. Conclusion and future perspectives

Due to an excellent antioxidant profile and a range of observed health benefits, astaxanthin has been incorporated into a range of food and pharmaceutical matrices. However, astaxanthin is highly unstable and loses its functionality during some food processing steps or during storage. Encapsulation and emulsification are useful techniques to protect astaxanthin during storage and processing. The optimization of these techniques on industrial scale is important to increase the efficiency and productivity of the biological properties. Low energy emulsification methods need more optimization, since these are effective in controlling the droplet size and encapsulation efficiency of astaxanthin. Important parameters that affect the stability of encapsulated astaxanthin include the composition of matrix, type of emulsifiers and stabilizers and the concentration of astaxanthin in the delivery medium.

Extraction and quantification of astaxanthin in encapsulated samples can be challenging, particularly since most of the astaxanthin extracts contain esterified astaxanthin rather than free astaxanthin and also have complex matrices that need to be quantitatively removed. Finally, most bioavailability and digestion studies with encapsulated astaxanthin involve stimulated gastric fluids, or different in vitro models, which are only indicators of bioavailability. More accurate bioavailability determination requires testing in human subjects or at least animal in vivo models to determine the effective bioavailability of specific encapsulation systems. Finally, for food grade applications formulations and ingredients are limited by both market and regulatory requirements, limiting the scope of methods and materials available for use in food systems. Further investigation and development of new food grade encapsulation materials is an important area of ongoing research.

Acknowledgments

Author NK acknowledges an Alfred Deakin Post-Doctoral Fellowship from Deakin University Australia.

References


Critical review of encapsulation methods

Khalid et al.

Figure 8. Studies depicting bioaccessibility and bioavailability of astaxanthin in emulsified forms. (a) Bioaccessibility study of emulsified astaxanthin with different emulsifiers, ML (modified lecithin) and CS (sodium caseinate), (b) Bioavailability studies in HT-29 cell lines of nanodispersed astaxanthin in food systems, and (c) Cellular uptake of carotenoids in different emulsified forms, Ast-Em.Tw (Tween 20 stabilized astaxanthin nanoemulsions), Ast-Em.wp (Whey proteins stabilized astaxanthin nanoemulsions), Ast-lip (astaxanthin loaded lipsomes), β-car and Lyc stands β-carotene and lycopene (Anarjan and Tan 2013a; Khalid et al. 2017b; Ribeiro et al. 2010).


